A Phase II Study of Lorlatnib in ROS1 Rearranged Advanced NSCLC

ClinicalTrials.gov processed this data on April 4, 2022. Link to the current ClinicalTrials.gov record.

Recruitment Status

UNKNOWN STATUS (See Contacts and Locations)
Verified April 2022 by National Cancer Center, Korea


National Cancer Center, Korea

Information Provided by (Responsible Party)

Ji-youn Han

Clinicaltrials.gov Identifier

Other Study ID Numbers: NCC-2018-0232
First Submitted: June 14, 2018
First Posted: August 2, 2018
Last Update Posted: April 6, 2022
Last Verified: April 2022
History of Changes

Listing a study on this site does not mean it has been evaluated by the U.S. Federal Government. The safety and scientific validity of a study listed on ClinicalTrials.gov is the responsibility of the study sponsor and investigators. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.

ClinicalTrials.gov, a resource provided by the U.S. National Library of Medicine (NLM), is a registry and results information database of clinical research studies sponsored or funded by a broad range of public and private organizations around the world. Not all studies listed on ClinicalTrials.gov are funded by the National Institutes of Health (NIH) or other agencies of the U.S. Federal Government. Not all listed studies are regulated and/or reviewed by the U.S. Food and Drug Administration or other governmental entities.

Information on ClinicalTrials.gov is provided by study sponsors and investigators, and they are responsible for ensuring that the studies follow all applicable laws and regulations. NLM staff do not verify the scientific validity or relevance of the submitted information beyond a limited quality control review for apparent errors, deficiencies, or inconsistencies.

Choosing to participate in a study is an important personal decision. Before you participate in a study, discuss all options with your health care provider and other trusted advisors. For more information about participating in clinical studies, see Learn About Clinical Studies, which includes questions that you might want to ask before deciding to participate in a study.

For more information about using the information on ClinicalTrials.gov, please also see Terms and Conditions.

See also the Web Policies and Notices for the NIH web site.

Study Description

ROS1 rearrangement characterizes a small subset (1-2%) of non-small cell lung cancer (NSCLC) and is associated with light or never smoking patients and adenocarcinoma histology. Recently, ROS1 inhibitors such as crizotinib and ceritinib demonstrated significant efficacy in ROS1 rearranged NSCLC. Thus, identification of ROS1 rearrangement in NSCLC is mandatory to permit ROS1 targeted therapy. However, current guidelines either do not refer to ROS1 testing or mention it briefly without making any strong recommendation. The detection of ROS1rearrangement is based on in situ (immunohistochemistry [IHC], fluorescence in situ hybridization [FISH]) and extractive non-in situ assays. While FISH still represents the gold standard in clinical trials, this technique may fail to recognize rearrangements of ROS1 with some gene fusion partner. On the other hand, IHC is the most cost-effective screening technique, but it seems to be characterized by low specificity. Extractive molecular assays are expensive and laborious methods, but they specifically recognize almost all ROS1 fusions using a limited amount of mRNA even from formalin-fixed, paraffin-embedded tumor tissues. Recently, Korean Heath Insurance Review and Assessment Service (HIRA) approved next generation sequencing (NGS)-based target sequencing for NSCLC patients, which may facilitate the detection of ROS1 rearrangement in Korean patients with advanced NSCLC.

Lorlatinib is a new, potent, brain-penetrant, ATP-competitive small molecule inhibiter of ALK/ROS1. However, the objective response rate (ORR) was 17/47 (36.2%; 95% CI 22.7, 51.5) in ROS1 arm of B7461001 study, but this result may not represent the ORR of lorlatinib as a 1st line treatment since 53% had central nervous system involvement at baseline and 72% of patients had received prior crizotinib. Therefore, given the activity of lorlatinib in ROS1 rearranged lung cancer, The investigator will investigate the efficacy of lorlatinib in ROS1 inhibitor-naïve patients with ROS1- rearranged NSCLC. The investigator will also investigate the efficacy according to fusion partners and resistance mechanisms. Finally, The investigator will compare the concordance among diagnostic tests including FISH, IHC and NGS-based target sequencing and provide the clinical guidance for diagnosis of ROS1 rearrangement in NSCLC.
Condition or Disease Intervention/Treatment
  • Nonsmall Cell Lung Cancer
  • Drug: Lorlatinib

Study Design

Study TypeInterventional
Anticipated Enrollment35 participants
Design AllocationN/A
Interventional ModelSingle Group Assignment
MaskingNone (Open Label)
Primary PurposeTreatment
Official TitleA Phase II Study of Lorlatnib in ROS1 Rearranged Advanced NSCLC
Study Start DateMay 2, 2019
Anticipated Primary Completion DateDecember 31, 2022
Anticipated Study Completion DateDecember 31, 2023

Groups and Cohorts

Group/ CohortIntervention/ Treatment
  • Lorlatinib
    • Subjects will be treated with lorlatinib 100mg PO daily. A cycle will be defined as 28-days for the convenience of analysis.
  • Drug: Lorlatinib
    • Subjects will be treated with lorlatinib 100mg PO daily. A cycle will be defined as 28-days for the convenience of analysis.

Outcome Measures

Primary Outcome Measures

  1. ORR [from Cycle1 Day 1 until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months").]
    To assess the clinical efficacy of lorlatinib as measured by ORR using RECIST criteria v 1.1

Eligibility Criteria

Ages Eligible for Study 18 Years and Older (Adult, Older Adult)
Sexes Eligible for Study All
Accepts Healthy Volunteers No
Inclusion Criteria
  • ia
  • Metastatic or recurrent NSCLC with ROS1 rearrangement identified by NGS-based target sequencing
  • Treatment naïve or one prior systemic treatment with platinum doublet chemotherapy
  • At least one measurable disease lesion according to RECIST 1.1
  • ECOG performance status 0-2
  • Age ≥ 18 years
  • Adequate hematologic, hepatic, and renal function
  • Written informed consent
  • 4.2
Exclusion Criteria
  • ife expectancy of less than 12 weeks
  • Prior treatment with a ROS1 inhibitor
  • Symptomatic uncontrolled brain metastasis
  • Other malignancy within 5 years, except for adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer treated surgically with curative intent, and ductal carcinoma in situ treated surgically with curative intent
  • Uncontrolled intercurrent illness
  • Pregnancy or unwillingness to use effective birth control
  • Known hypersensitivity to lorlatinib and/or its excipients

Contacts and Locations

Sponsors and Collaborators National Cancer Center, Korea
  • National Cancer Center | Goyang-Si, Gyeonggi-do, Korea, Republic of, 10408
  • Principal Investigator: Ji-Youn Han, MD.Ph.D., National Cancer Center

More Information

Additional Relevant MeSH Terms

  • Carcinoma, Non-Small-Cell Lung
  • Carcinoma, Bronchogenic
  • Bronchial Neoplasms
  • Lung Neoplasms
  • Respiratory Tract Neoplasms
  • Thoracic Neoplasms
  • Neoplasms by Site
  • Neoplasms
  • Lung Diseases
  • Respiratory Tract Diseases